Stonepine Capital Management, LLC Buys Amryt Pharma PLC, CTI BioPharma Corp, Chiasma Inc, Sells KalVista Pharmaceuticals Inc, DiaMedica Therapeutics Inc, PLx Pharma Inc

• New Purchases: AMYT, ANGN, CDTX, NBSE, SCYX,
• Added Positions: CTIC, CHMA, SBBP, CBIO, CELC, CFMS, GMDA, YMTX, XOMA,
• Reduced Positions: KALV, DMAC, APEN, ADMS, ISEE, OVID, AFMD, CFRX, AGTC, CRVS, XGN, EYPT,
• Sold Out: PLXP, AYTU, APVO, GLPG, BWAY, ONCS,

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/stonepine+capital+management%2C+llc/current-portfolio/portfolio

1. Amryt Pharma PLC (AMYT) - 2,797,744 shares, 17.75% of the total portfolio. New Position
2. Chiasma Inc (CHMA) - 6,770,000 shares, 16.75% of the total portfolio. Shares added by 37.04%
3. CTI BioPharma Corp (CTIC) - 7,632,530 shares, 9.98% of the total portfolio. Shares added by 131.75%
4. Adamas Pharmaceuticals Inc (ADMS) - 2,694,295 shares, 7.44% of the total portfolio. Shares reduced by 21.18%
5. Catalyst Biosciences Inc (CBIO) - 3,076,376 shares, 6.97% of the total portfolio. Shares added by 25.56%

Stonepine Capital Management, LLC initiated holding in Amryt Pharma PLC. The purchase prices were between $10.9 and $14.29, with an estimated average price of $12.44. The stock is now traded at around $11.840000. The impact to a portfolio due to this purchase was 17.75%. The holding were 2,797,744 shares as of 2021-06-30.

Stonepine Capital Management, LLC initiated holding in Angion Biomedica Corp. The purchase prices were between $13.02 and $18.07, with an estimated average price of $14.55. The stock is now traded at around $9.440000. The impact to a portfolio due to this purchase was 1.52%. The holding were 222,836 shares as of 2021-06-30.

Stonepine Capital Management, LLC initiated holding in Cidara Therapeutics Inc. The purchase prices were between $1.87 and $2.7, with an estimated average price of $2.13. The stock is now traded at around $2.070000. The impact to a portfolio due to this purchase was 1.28%. The holding were 1,211,286 shares as of 2021-06-30.

Stonepine Capital Management, LLC initiated holding in NeuBase Therapeutics Inc. The purchase prices were between $4.63 and $7.39, with an estimated average price of $5.57. The stock is now traded at around $3.730000. The impact to a portfolio due to this purchase was 0.08%. The holding were 31,070 shares as of 2021-06-30.

Stonepine Capital Management, LLC initiated holding in SCYNEXIS Inc. The purchase prices were between $6.5 and $9.97, with an estimated average price of $7.92. The stock is now traded at around $6.140000. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 100 shares as of 2021-06-30.

Stonepine Capital Management, LLC added to a holding in CTI BioPharma Corp by 131.75%. The purchase prices were between $2.16 and $2.91, with an estimated average price of $2.41. The stock is now traded at around $2.710000. The impact to a portfolio due to this purchase was 5.67%. The holding were 7,632,530 shares as of 2021-06-30.

Stonepine Capital Management, LLC added to a holding in Chiasma Inc by 37.04%. The purchase prices were between $2.82 and $4.76, with an estimated average price of $3.76. The stock is now traded at around $3.760000. The impact to a portfolio due to this purchase was 4.53%. The holding were 6,770,000 shares as of 2021-06-30.

Stonepine Capital Management, LLC added to a holding in Strongbridge Biopharma PLC by 641.67%. The purchase prices were between $2.27 and $3.15, with an estimated average price of $2.64. The stock is now traded at around $2.130000. The impact to a portfolio due to this purchase was 4.44%. The holding were 3,305,617 shares as of 2021-06-30.

Stonepine Capital Management, LLC added to a holding in Catalyst Biosciences Inc by 25.56%. The purchase prices were between $4.1 and $5.33, with an estimated average price of $4.59. The stock is now traded at around $4.130700. The impact to a portfolio due to this purchase was 1.42%. The holding were 3,076,376 shares as of 2021-06-30.

Stonepine Capital Management, LLC added to a holding in Celcuity Inc by 100.72%. The purchase prices were between $14.25 and $30.93, with an estimated average price of $25.41. The stock is now traded at around $21.595000. The impact to a portfolio due to this purchase was 1.38%. The holding were 218,951 shares as of 2021-06-30.

Stonepine Capital Management, LLC added to a holding in Conformis Inc by 49.51%. The purchase prices were between $0.79 and $1.34, with an estimated average price of $0.95. The stock is now traded at around $1.342100. The impact to a portfolio due to this purchase was 1.32%. The holding were 6,626,085 shares as of 2021-06-30.

Stonepine Capital Management, LLC sold out a holding in PLx Pharma Inc. The sale prices were between $9 and $15.94, with an estimated average price of $11.81.

Stonepine Capital Management, LLC sold out a holding in Aytu BioPharma Inc. The sale prices were between $4.73 and $7.6, with an estimated average price of $5.91.

Stonepine Capital Management, LLC sold out a holding in Aptevo Therapeutics Inc. The sale prices were between $21.85 and $30.52, with an estimated average price of $25.55.

Stonepine Capital Management, LLC sold out a holding in Galapagos NV. The sale prices were between $68.86 and $83.34, with an estimated average price of $76.32.

Stonepine Capital Management, LLC sold out a holding in BrainsWay Ltd. The sale prices were between $8.25 and $11.62, with an estimated average price of $9.77.

Stonepine Capital Management, LLC sold out a holding in OncoSec Medical Inc. The sale prices were between $2.81 and $5.43, with an estimated average price of $4.15.